Background: Ulcerative colitis (UC) is associated with significant health care utilization and costs. We assessed UC direct medical costs in Quebec,
The anti-TNFa infliximab, adalimumab, and golimumab are approved in Canada to treat IBD (CD and UC). Because of their high acquisition cost, these medications are listed on the Quebec drug formulary as "exceptional drugs" for CD. This requires physicians to fill a form to justify their prescription for each patient with CD. Patients with UC who have failed conventional 5-ASA and immunomodulator treatments receive approval for anti-TNFa use as "exceptional patients" on a case-per-case basis. 22 The direct medical costs of UC are substantial. [23] [24] [25] [26] Frequent outpatient physician visits, emergency department (ED) visits, hospitalizations, in particular those for colectomy, and high medication costs are currently the largest contributors. 27 Despite its high financial burden on the health care systems, no previous study has assessed the cost of UC in the Quebec population. [28] [29] [30] [31] [32] Little data exist on the change in health resources utilization and costs with the introduction of the anti-TNFa agents in patients with UC. 29 We assessed the direct medical cost (medication, physician billings, ED visits, and hospitalizations) of UC among adult patients in the Canadian province of Quebec from the perspective of the provincial health care system in 2 time periods (1998-2004 and 2005-2011) reflecting eras before and after the utilization of anti-TNFa treatment in UC. Our prespecified hypotheses were (1) a lower number of colectomies will be observed in 2005-2011 compared with 1998-2004; and (2) the decrease in colectomy-associated costs will be offset by the increased medication cost associated with anti-TNFa use.
MATERIALS AND METHODS

Data Sources
We used demographic, physician, and pharmacy claim records obtained from the Quebec Health Insurance Agency, the Régie de l'assurance maladie du Québec (RAMQ) and hospitalization records obtained from the hospital abstract summary database (Med-Echo, housed at RAMQ). Hospitalization cost data were obtained from the Ministère de la santé et services sociaux (MSSS)-the All Patient Refined Diagnosis Related Groups (APR-DRGs) database. 32 In Quebec, all residents are covered by RAMQ for outpatient and inpatient physician services. In addition, drug insurance is mandatory for all residents. RAMQ provides drug insurance to all residents aged 65 years or older (1,232,985 individuals), all individuals who receive social assistance (476,535 individuals), and those in the working force who do not have private drug insurance through their employer or a family member's plan (1, 777 ,754 individuals). 33 
Study Population
We obtained information on all Québec residents 20 years of age or older who had a minimum of 2 physician claims or 1 hospitalization with a UC diagnosis code (primary or secondary) and who were registered with RAMQ drug plan anytime between January 1998 and December 2011. The International Classification of Diseases (ICD) versions 9 and 10 were used to identify UC (ICD-9: 556.xx; ICD-10: K51.xx).
Study Cohorts
Because anti-TNFa use may greatly influence the cost of UC, we conducted 2 separate retrospective cohort studies defined over January 1998 to December 2004 (preperiod) and January 2005 to December 2011 (postperiod), respectively. We describe the study cohort in the postperiod; the preperiod cohort was assembled similarly. The postperiod cohort included adult patients (age $ 20 yr) who between January 2005 and December 2011 had at least 4 diagnoses of UC in physician claims in a 2-year period or 1 hospital diagnosis for UC (primary or secondary). 1 Patients who received both a diagnosis for CD and for UC in the 2-year period were classified according to a scoring system that was developed and validated in the Canadian province of Manitoba. 34 Patients with UC were considered at the date of their first UC diagnosis in the study period (index date). Those covered by the provincial drug plan for at least 1 year before their index date were included. Those who received a diagnosis for either CD or UC in the previous year and those who used antiTNFa, immunomodulators, or 5-ASA medications in the previous year were excluded (Fig. 1) . Therefore, the cohort included new patients with UC and those patients who were in remission in the previous year. Patients were followed from their index date to death, end of the study period, or the first date of their drug coverage interruption (a gap of 2 mo in their drug coverage), whichever came first.
Outcomes-Direct Medical Costs
The total direct medical cost was the primary outcome. The total direct medical cost was calculated for each cohort during the corresponding study period (1998-2004 and 2005-2011) , respectively. For each patient, the total direct medical cost was the sum of the hospitalizations cost, costs for dispensed medications, and costs for outpatient and ED physician services. The costs of dispensed medications included the costs for 5-ASA (mesalamine and olsalazine), immunomodulators (mercaptopurine and azathioprine), other UC medications (disease-modifying antirheumatic drug that may also be used in UC when treatment with mercaptopurine and azathioprine fails: sulfasalazine, methotrexate, and cyclosporine), antiTNFa (infliximab and adalimumab; golimumab was not yet available during the study period), corticosteroids (prednisone, hydrocortisone, budesonide, prednisolone, and methylprednisolone), and gastroprotective agents ([GPAs], proton pump inhibitors, and histamine-2 receptor blocker). GPAs were included because their utilization was believed to be for symptom relief. The total cost of outpatient physician visits included the costs of visits to gastroenterologists and visits to any other physician (e.g., general practitioner, internist, and surgeon), where the diagnosis (ICD-9 code) was for a gastrointestinal (GI) disorder. The GI disorders considered are listed in Appendix 1, Supplemental Digital Content 1, http://links.lww.com/IBD/B509. Similarly, the total cost of ED visits included the costs of visits that required a gastroenterologist examination and visits where the diagnosis was for a GI disorder (see Appendix 1, Supplemental Digital Content 1, http://links.lww.com/IBD/B509). The total cost of hospitalizations included those for colectomy and those where the primary or secondary diagnosis was for a GI disorder (see Appendix 1, excluding colectomy, Supplemental Digital Content 1, http://links.lww.com/IBD/B509). Med-Echo contains information on all hospital admissions. Records include primary and up to 15 secondary discharge diagnoses coded according to ICD-10 codes since April 2006 (ICD-9 codes before that date).
The costs of prescribed medications were available from the RAMQ data. They included the pharmacist fee, RAMQ reimbursement, and patient out-of-pocket contribution. The costs of physician visits were the reimbursement costs for physician feefor-service claims available from the RAMQ data. The cost of hospitalizations was the sum of the physician claims during that hospitalization plus the product of the niveau d'intensité relative des ressources utilisées (NIRRU) associated to that hospitalization times the unit cost per NIRRU (physician claims + NIRRU x unit cost per NIRRU). The NIRRU and unit cost per NIRRU were provided in the APR-DRG data. The MSSS-APR-DRGs database includes an indicator of the level of health services utilization intensity for all hospitalizations and ED visits, NIRRU; unit costs per NIRRU are provided per year. 35 The cost of colectomy included the cost of total abdominal colectomy, completion proctectomy, and pouch performed in 1, 2, or 3 surgeries. The cost of an ED visit was the sum of the physician claims for that visit plus the cost associated with 1 NIRRU (as provided by the APR-DRG data).
Direct medical costs were converted to 2012 Canadian dollars using the Health Component of the Canadian Consumer Price Index. 
Patient Baseline Characteristics
Statistical Analyses
The following analyses were conducted separately in each of the study periods: Descriptive analyses (mean and SD or proportion) were used as appropriate to report baseline patient characteristics and unadjusted cost data by study period. Logistic regression models were used to compare patient baseline characteristics between the 2 periods. Generalized regression models with log link and gamma distribution 38 were used to compare costs between the 2 periods adjusting for patient characteristics at baseline. The influence of cost outliers on the results of the models was examined by removing the outliers and repeating the analyses. The main analyses report the results with outliers removed, and additional analyses report the results including outliers.
Subgroup analyses were conducted, separating patients 65 years and older from the younger patients. Sensitivity analyses were conducted, first by considering GI hospitalizations with GI coded as principal diagnosis (removing those hospitalizations where the GI was a secondary diagnosis code); second, by completely removing GI hospitalizations (other than those for colectomy); and third, by considering another UC case definition and repeating all analyses. In this definition, a patient with UC was one with 2 physician claims for UC in a 2-year period or 1 diagnosis code in a hospital discharge summary. 39, 40 All statistical analyses were performed using SAS version 9.3 for UNIX (SAS Institute Inc., Cary, NC).
Ethical Considerations
Approval to conduct the study was obtained from the Quebec Ethics Review Agency, the Commission d'accès à l'information, and the McGill University Health Centre Ethics Review Board.
RESULTS
Description of Cohorts
The initial database search yielded 5410 patients with UC identified in the postperiod at their first date of diagnosis (index date) and 5102 patients in the preperiod. Among these, 2141 patients in the postperiod were covered by the RAMQ drug plan for the year before their index date and 1986 patients in the preperiod. In total, 801 patients in the postperiod and 716 in the preperiod met the inclusion/exclusion criteria and were included (Fig. 1) . Table 1 describes the baseline characteristics of each cohort. Both cohorts spanned a similar time period of a maximum of 7 years (median follow-up of 3 yr). Overall, cohorts were predominately women and were comparable in terms of age (mean age 6 SD: 61.8 6 19.5 yr in the preperiod and 60.4 6 18.4 yr in the postperiod). A large percentage of patients (42% in the preperiod and 43% in the postperiod) had low income. Comorbidities, including blood disease, cancer, and peptic ulcer disease, were largely similar between the preperiod and postperiod. The cohorts were also similar on previous medication use in general. 
Clinical Events and Direct Medical Costs
The total number of patients with the events of interest (medications: 5-ASA, immunomodulators, other UC mediations, anti-TNFa, corticosteroids, and GPA; outpatient physician and ED visits; and colectomy and other GI hospitalizations) and the mean daily crude costs of these events in each cohort are displayed in Table 2 Table 2 ). In addition to colectomies, the average daily cost of all other GI hospitalizations and ED visits for the various GI disorders considered (see Appendix 1, Supplemental Digital Content 1, http://links.lww.com/IBD/B509) also decreased. Among hospitalizations with a GI disorder as the principal reason for admission (i.e., excluding from the main analyses those hospitalizations where the GI diagnosis was only a secondary diagnosis), we also observed a decrease in the average daily cost in the postperiod versus the preperiod. The average daily cost of GI outpatient services remained relatively constant between the 2 periods.
Adjusted Cost Ratios
Because cost data were highly skewed (departed substantially from normal distribution), generalized linear models with log link and gamma distribution were used to compare mean daily costs between the preperiod and postperiod. Table 3 shows the daily cost ratios (95% confidence interval [CI]) adjusted for patient baseline characteristics. The adjusted daily cost was significantly lower in the postperiod versus preperiod (0.75; 0.67-0.85). Older age at diagnosis, low income, and lower SES quintiles were associated with increased costs. Use of other UC medications (1.41; 1.04-1.91), GPAs (1.17; 1.02-1.35), and antidepressants (1.37; 1.17-1.61) in the previous year were associated with increased costs. Women, previous NSAID users, and those who visited a gastroenterologist in the previous year incurred lower costs.
Fifty-five outliers (costs outside the expected range) identified by the model were removed in the main analysis. Including these 55 patients in the model did not significantly alter the results (cost ratio for postperiod versus preperiod: 0.67; 95% CI, 0.58-0.77).
Subgroup and Sensitivity Analyses
In subgroup analyses, we separated patients into those who were 65 years and older and those younger than 65 years. The total number of patients with the events of interest and the mean daily crude costs of these events in each cohort are displayed by these subgroups in Appendix 2, Supplemental Digital Content 1, http://links.lww.com/IBD/B509. The adjusted daily costs in the postperiod versus preperiod were significantly lower only among those 65 years of age and older (cost ratio for postperiod versus preperiod: 0.41; 95% CI, 0.34-0.50) but not in those younger than 65 years (1.06; 0.87, 1.28) (data not shown).
In sensitivity analyses, removing the costs of GI hospitalizations where the GI code was a secondary diagnosis revealed results similar to those of the main analysis (cost ratio for postperiod versus preperiod: 0.74; 95% CI, 0.66-0.84); completely removing the costs of GI hospitalizations (other than those for colectomy) resulted in a lower cost ratio for the postperiod versus preperiod (0.81; 0.72, 0.91). 41 Using a more common definition for a chronic disease to identify patients with UC (2 diagnoses codes in physician claims in a 2-yr period or 1 diagnosis code in a hospital discharge summary), 34, 39, 40 2265 patients were included in the postperiod and 1885 patients in the preperiod. The total cost of UC in the postperiod was $50,454,940 
DISCUSSION
Our study assessed UC-related direct medical costs among patients with UC 20 years of age or older in 2 time periods, before (1998) (1999) (2000) (2001) (2002) (2003) (2004) and after (2005-2011) anti-TNFa use. Study patients were newly diagnosed as per the criteria used. More patients were included in the postperiod (801 patients) compared with the preperiod (716 patients). Reasons for the observed increase in the number of patients were not clear and may include a closer follow-up of patients (i.e., more people met the 4 claims in the 2-yr criterion), a better discrimination between CD and UC early on and/or an increased RAMQ drug plan enrollment in this population. UC-related direct medical costs were assessed in these patients over a median follow-up of 3 years (maximum 7 yr) in both preperiod and postperiod. Study patients incurred a substantial UC-related direct medical cost, totaling $21,387,262 (followup time 858,321 d; median and mean daily costs $16.96 and $59.34, respectively) in the postperiod and $18,496,014 in the preperiod (follow-up time 741,955 d; median and mean daily costs $18.65, $99.34, respectively). In adjusted models, the cost in the postperiod was 25% lower than that in the preperiod.
The overall decrease in cost observed in our study in the postperiod versus preperiod was unexpected. Longer follow-up was observed in the postperiod versus preperiod, suggesting that more patients were diagnosed early on in the postperiod. The cost decrease cannot be explained by differences in baseline patient characteristics because these were similar in general in the postperiod versus preperiod. Differences between the 2 periods were observed in previous NSAID and GPA use and previous IHD. However, these were adjusted for in the cost model. The number of our study patients who used anti-TNFa medications in the postperiod was small (53/801 ¼ 7%). This perhaps reflects the number of individuals in serious condition in whom 5-ASA and immunomodulators alone or in combination have failed. The requirement of RAMQ preapproval of anti-TNFa's prescription for patients with UC and the high costs of these medications (implying a high patient copayment) may also have contributed, at least in part, to their relatively low use. Other Canadian (5.0%) 42 and French (7.4%-12.9%) 43 studies have reported similar rates of anti-TNFa use in patients with UC. Increased overall costs have been suggested with increased use of antiTNFa in patients with UC in another study. 26 However, this cannot be verified in our study because the magnitude of increase in anti-TNFa and the potentially associated changes in other GI services utilization are not available. 26 A population-based study conducted in the Canadian province of Manitoba showed similar overall costs, although the change in UC cost after anti-TNFa introduction was not assessed in that study. 44 In a US study, the annual per capita mean direct medical cost of UC was $US 7827 (evaluated from 1996 to 2011). 45 In our study, the per capita mean direct medical cost of UC from 2005 to 2011 (postperiod) was $26,701, and the average follow-up was 858,321/(365 · 801) ¼ 3 years. Therefore, the annual per capita mean direct medical cost may be estimated in our study at 26,701/3 ¼ $CAN 8,900, which is similar to the US estimate. In a systematic review published in 2011, the annual per capita direct medical cost of UC (in 2008 currency) ranged from $US 6217-$US 11,442 in the US, $CAN 4988 in Alberta, Canada, and €2210-€10,395 in Europe. 28 None of these studies assessed the change in UC cost after anti-TNFa introduction. Our cost estimates fall within the US and European ranges. Cost differences between these studies (all conducted before 2005) and ours highlight differences in health care financing and delivery systems, as well as the methodologies used to estimate these costs. The Canadian study conducted in Alberta and published in 1988 46 was based on survey data that may have suffered from participation and recall biases, which may explain at least partly the difference in cost found in that study and ours.
The observed decrease in the average daily cost in the postperiod versus preperiod in our study was primarily due to a decrease in corticosteroid use and in the number of GI hospitalizations, colectomies, and UC-related ED visits. Hospitalizations have primarily been shown to be a large driver in the cost of UC. 28 UC-related hospitalization rates have been shown to decrease by half with anti-TNFa use. 18, 47 In addition, infliximab, but not adalimumab has been found to significantly decrease the risk of colectomy. 47 Anti-TNFa use has also been associated with a decrease in corticosteroid use in patients with IBD; this decrease implies cost saving for corticosteroid acquisition and for treating its side effects. 48 However, our study did not investigate such association and cannot corroborate these hypotheses. In addition, because of the low number of anti-TNFa users in our study, further investigation is required to determine the antiTNFa-attributable change in cost.
A decrease in 5-ASA and an increase in immunomodulator use were observed in the postperiod versus preperiod, perhaps indicating a more aggressive management of UC in the postperiod. Other UC medications (sulfasalazine, methotrexate, and cyclosporine) use was low and similar between the postperiod (40/801 ¼ 5%) and preperiod (38/716 ¼ 5%). Other UC medications may be used as add-on to immunomodulators or antiTNFa medications for patients with UC who do not respond to these medications alone or to prevent immunogenicity. 49, 50 The reduction in the number of colectomy hospitalizations (60, 7.5% in the postperiod versus in the preperiod 79, 11%) suggests perhaps a change in management of patients with UC after the introduction of anti-TNFa medications. These medications offer a possible alternative to colectomy for at least a period of time that may vary between patients. A decrease in the incidence rate of colectomy for medically refractory UC was also observed since 2005 in another Canadian study conducted in Alberta based on a chart review. 51 This study did not assess the associated costs. The mean cost per colectomy also decreased in the postperiod versus the preperiod, as reflected by the 22% reduction in the cost per colectomy in the postperiod. Good response to anti-TNFa has been shown to decrease the rate of proctocolectomy substantially. 52 However, whether this is a delay in the cost down the road or a true cost reduction cannot be determined from our study; the lifelong cost of anti-TNFa may well outweigh a short-term saving in surgery expenditure. 23 Nonetheless, a lifelong use of anti-TNFa also means that the patient has avoided colectomy.
The number of patients included in our study is lower than that extrapolated from the 10.1 per 100,000 patient-years incidence rate reported by another study of UC in Quebec. 1 Our study included only the patients who were registered with the public drug plan for the whole study period to capture their medication utilization and costs. In addition, our study patients were newly diagnosed or had a new UC episode (no UC or CD diagnosis and no colectomy or a pharmacologic treatment with 5-ASA, anti-TNFa, and immunomodulators in the previous year) (Fig. 1) . As seen in Figure 1 , many patients were excluded for using these medications in the previous year without having had a physician claim or hospitalization for UC or CD in that year.
Our cohorts had over 40% of patients in the low-income group in both periods. This is higher than the proportion of those who receive social assistance in the Quebec general population. 22 Higher unemployment, sick leave, and permanent work disability rates have been reported among patients with IBD compared with the general population. [53] [54] [55] In our study, the cost was lower among women versus men, which has not been explicitly reported in the literature. In some studies, women were more likely to see a doctor for IBD 56 and more likely to have surgical complications, 57 although in others, male sex was associated with higher ileal-pouch-anal-anastomosis complications. 58 Men were also more likely than women to be prescribed anti-TNFa in another study, which may explain some of the elevated cost in men. 59 Nonetheless, further investigation is needed to delineate sex differences regarding UC treatment and complications.
In our study, older patients incurred higher costs than younger patients. Similar results were reported in a previous study by Bickston et al. 60 In that study, patients older than 65 years were the second most expensive group after the pediatric group. Older patients have more comorbidities in general and higher risk of medication nonresponse and intolerance, which may explain this result. However, a study conducted in the Netherlands reported lower direct medical costs in patients older than 60 years compared with younger patients. 61 Participation rate among those younger than 60 years may have been higher among those who were severe in that study. Of note, in our study, the total cost of medications, physician visits, and hospitalizations for colectomies was higher in those younger than 65 years compared with those older; only the cost of GI hospitalizations and the costs of GPAs were higher in the older group (see Appendix 2, Supplemental Digital Content 1, http://links.lww.com/IBD/B509).
Previous antidepressant use was associated with increased UC-related direct medical costs in our study. Other studies have shown temporal associations between UC and mental disorders, in particular, anxiety and depression, a high correlate of disease severity. [62] [63] [64] [65] In addition, anxiety and depression are associated with treatment nonadherence, which in turn has been associated with higher health services use and costs in patients with UC. 65, 66 In our study, a high proportion of patients used NSAIDs in the previous year in both postperiod (31%) and preperiod (24%). Accumulating evidence concerning the association of some NSAIDs with IHD and the withdrawal of rofecoxib from the market in 2004 may explain the drop between the preperiod and postperiod. 67 NSAIDs are contraindicated in severe IBD because of their association with exacerbating UC flare-ups. 2 To further understand this association, we also examined the number of NSAID users in follow-up. In the preperiod, 33% of patients used NSAIDs in follow-up (17% were not using NSAIDs in the previous year and 16% were), whereas 27% used NSAIDs in follow-up in the postperiod (15% were not using NSAIDs before and 12% were). Therefore, in both periods, half of the patients who used NSAIDs in the previous year had stopped using them in follow-up, whereas a higher percentage of users in follow-up did not use NSAID in the previous year, which may explain, at least in part, the lower cost observed among previous NSAID users. The unresolved controversy surrounding this association 68 and having limited alternatives for pain control for IBD-related arthritis may explain the high utilization.
In our study, a patient with UC was one who had at least 4 UC diagnoses in physician claims in a 2-year period or 1 hospital diagnosis of UC in the hospital abstract summary database, a definition that was also used by other Canadian studies. 1, 34 Other case definitions exist for identifying patients with UC from an administrative database. Two or more claims during a study period of 4 years were used in one study. 41 A more common definition for a chronic disease requires 2 diagnoses codes in physician claims in a 2-year period or 1 diagnosis code in a hospital discharge summary. 39, 40 Using this definition in our study, a cost decrease was also observed in the postperiod versus preperiod.
The strengths of this study include its population-based approach using provincial, administrative databases which limit the possibility of recall bias and missing information. Our study also assessed all costs from the perspective of a single payer health care system using actual reimbursement data for physician services and prescribed medications and ED and hospital cost data obtained from the Quebec Ministry of Health databases. The use of a validated algorithm with 78.0% sensitivity (95% CI, 75.7-80.1) and 99.8% specificity (95% CI, 99.7-99.9) to identify all adult patients with UC in 2 time periods before and after the utilization of anti-TNFa and the relatively long follow-up of up to 7 years are also strengths of our study. Cost data used in our study were provided by the provincial health insurance agency and allowed for the assessment of real-time costs and robust adjusted comparisons between 2 time periods, which have not been examined in Quebec previously. We were also able to show a cost breakdown by medication and health services use, which allows for better generalizability and comparison with similar studies conducted elsewhere. Nonetheless, our study has some limitations. First, although the sensitivity of the algorithm we used was high (78%), it was not perfect and means that our study missed about 22% of the patients with UC. However, the comparable cost ratio that we found when we used a more sensitive (but less specific) algorithm and the nondifferential coding between the postperiod and preperiod indicates that missing some UC cases in each period would not substantially affect the cost comparison between the 2 periods. A second limitation of our data is the lack of information on disease activity and severity, which precluded cost comparison by disease severity. Third, other health services and drug and vitamin utilization may have been related to UC but have not been included in our study. These may include iron and vitamin supplements, increased vaccination, and increased hospital admission for pneumonia. 69, 70 Fourth, our study included only the patients registered with the provincial drug plan. Therefore, results may not be generalizable to individuals who have private drug insurance. In a US study, publicly insured patients with UC incurred a higher cost over privately insured. 45 However, this result may not apply to our population, as all patients in Quebec are publically insured for their physician visits and hospitalizations. Although not all are publically insured for their medications, private insurance companies tend to list the same medications as RAMQ with similar reimbursement conditions. In addition, working individuals covered by the RAMQ drug plan include the self-employed and those working in smaller companies; those who do not differ in their SES from those covered by private drug insurance, and our results were adjusted for SES. Finally, our study did not assess indirect costs, which may be an important component of the UC burden and should be assessed in future studies. Moreover, our study did not assess the risks and costs of anti-TNFa adverse events such as tuberculosis and other opportunistic infections. 71 Future works should investigate these risks and their associated costs. Future works should also consider longer follow-up periods, as patients with UC who respond to anti-TNFa drugs can lose response over time. 72 In conclusion, the cost of UC has decreased from 2005 to 2011 as compared to 1998 to 2004, but remains substantial in Quebec. This decrease was primarily due to a decrease in colectomy and other GI hospitalizations and ED visits. Whether this decrease would be maintained with increased long-term antiTNFa use is not clear.
